This is because these therapies can stimulate the expression of pro-apoptotic proteins via activation of the p53 pathway or inhibit the expression of other BCL-2 anti-apoptotic proteins (such as MCL-1 by paclitaxel) to make cancer cells more dependent on BCL-xL for survival [8, 11]. The gene discussed is BCL2; the disease is cancer.